Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

46 results about "Low copy number" patented technology

Low Copy Number (LCN) is a DNA profiling technique developed by the UK Forensic Science Service (FSS) which has been in use since 1999. In the United Kingdom use of the technique was suspended between 21 December 2007 and 14 January 2008 while the Crown Prosecution Service conducted a review into its use - this suspension has now been lifted.

CA16 infectious clone with green fluorescent protein gene as well as construction method and application of CA16 infectious clone

The invention discloses a CA16 infectious clone with a green fluorescent protein gene as well as a construction method and an application of the CA16 infectious clone. The method comprises the steps of firstly, inserting full-length cDNA (complementary deoxyribonucleic acid) of a CA16 / GD09 / 24 virus strain by taking a low copy number plasmid pACYC177 as a carrier; then, inserting an eGFP (enhanced green fluorescent protein) reporter gene and adding a 2A protease cleavage site (AITTL) between 5'UTR and VP4 by taking the full-length infectious clone as a skeleton so as to obtain a full-length infectious clone of the CA16 with the eGFP reporter gene. The CA16 infectious clone with the green fluorescent protein gene, constructed by the method, disclosed by the invention, can be used for saving an eGFP-CA16 reporter virus of which the growth tendency is similar to that of a recombinant CA16 virus and a parent CA16, and can also be used for screening antiviral drugs, thereby providing a convenient platform for deepening virus replication and pathogenesis researches and laying a solid foundation for screening and developing novel vaccines in future.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI

Construction and use of catalogued nucleic acid libraries that contain advantageously adjusted representations of defined components

A process for constructing a catalogued nucleic acid library in which the proportional representation of the constituents is adjusted to advantage through the use of disclosed technologies for positive and negative selection. The resultant benefit is that significantly fewer library constituents will need to be screened in order to identify a potentially desired constituent. Moreover, library constituents that previously would have been essentially “lost” are now recoverable. Preferred embodiments of this invention include the cataloguing, normalization, and enrichment of library constituents. By way of example, but not limitation, this technology is serviceable for constructing a library that contains an adequate representation of desirable constituents that (1) are initially found in low-copy numbers within a sample source or (2) originate from an organism that is problematic to culture. Applicable uses of this invention include any library-screening endeavor previously hindered by logistical impediments.By expanding previous logistical frontiers this invention allows for a novel generation of previously unattainable molecules—particularly molecules that are “unclonable” from conventional, unadjusted libraries—to now be detected, cloned, manipulated, expressed, studied, and used. By disclosing the construction and screening of high yielding nucleic acid libraries from mixed and uncultivated organisms, the instant technology eclipses former boundaries in the area of biological discovery and enables the full breadth of biological diversity to be accessed in the search for previously undiscovered genes and gene products. The benefits of the present invention are seen to extend to areas of diagnosis, medicine, agriculture, manufacturing, and academia.
Owner:BP CORP NORTH AMERICA INC

Kit and extraction method for extracting micro ribonucleic acid (RNA)

The invention relates to the technical field of organisms, and particularly relates to a kit and an extraction method for extracting micro ribonucleic acid (RNA). The kit comprises a box body, a reagent bottle containing first magnetic bead liquid, a reagent bottle containing second magnetic bead liquid, a reagent bottle containing lysate, a reagent bottle containing an eluent, and a reagent bottle containing a scrubbing solution, wherein a foam pad is arranged on the inner bottom wall of the box body; the edge of the foam pad is attached to the inner lateral wall of the box body; five grooves are arranged on the foam pad; one reagent bottle is respectively arranged inside each groove; the first magnetic bead liquid contains a plurality of first magnetic beads, and a targeting sequence or a random sequence capable of being paired with the micro RNA is modified on the surface of each magnetic bead; the second magnetic bead liquid contains a plurality of second magnetic beads, and a hydrophilic high-molecular polymer with negative charge is modified on the surface of each magnetic bead. By adopting the kit disclosed by the invention, the micro RNA in plasma or serum can be more efficiently extracted, and the kit is especially applicable to extraction of the micro RNA with low content or low copy number in a plasma or serum sample.
Owner:SHANGHAI DIDA BIOTECH

Method and device for jointly detecting SNV, CNV and FUSEON variations

The invention relates to a method and device for jointly detecting SNV, CNV and FUSEON variations. More specifically, the device comprises a sequencing data reading module, an SNV detection module, a CNV detection module, a FUSEON variation detection module and a result output module, wherein the CNV detection module comprises a BAF calculation module, a BAF correction module, a BAF separation and identification module, a sequencing depth calculation module, a logR correction module, a logR background noise calculation module and a CNV judgment module. The method and device, based on BAF+logR information, detect the SNV, CNV and FUSEON variations in a sample with an extremely low ctDNA proportion, especially the CNV variation with low copy number amplification, with high sensitivity and high specificity.
Owner:上海思路迪医学检验所有限公司

QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- cMethDNA, REAGENTS, AND ITS USE

ActiveUS20150094222A1Evaluate responsePotential to evaluate response to treatmentSugar derivativesNucleotide librariesBlood plasmaPolynucleotide
The cMethDNA method of the present invention is a novel modification of the QM-MSP method (U.S. Pat. No. 8,062,849), specifically intended to quantitatively detect tumor DNA (or other circulating DNAs) in fluids such as serum or plasma at the lowest copy number yet reported. Unique compared to any other PCR-based assay, a small number of copies of a synthetic polynucleotide standard (STDgene) is added to an aliquot of patient serum. In a standard procedure, a cocktail of standards for a plurality of genes of interest (TARGETgene) is added to a sample of serum. Once total DNA is purified and processed, a PCR (multiplex step) is performed wherein the STDgene and the TARGETgene are co-amplified with the same external primer set. In the N second nested PCR step, amplicons present in a dilution of the first PCR reaction are subjected to real time PCR, and quantified for each gene in one well by two-color real-time PCR. Products are calculated by absolute quantitation with internal primer sets specific for the methylated TARGETgene and associated STDgene. Methods of making the STDgene standards and the use of the cMethDNA methods and kits containing the same are disclosed.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products